|
|
Volumn 40, Issue 11, 2001, Pages 709-713
|
|
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses
a a a a |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DICLOFENAC;
DRUG VEHICLE;
HYALURONIC ACID;
PLACEBO;
ACTINIC KERATOSIS;
ARTICLE;
CANCER STAGING;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG FORMULATION;
DRUG SAFETY;
DRUG TOLERABILITY;
FOLLOW UP;
GASTROINTESTINAL DISEASE;
GEL;
HEMATOLOGIC DISEASE;
HUMAN;
INVASIVE CARCINOMA;
LYMPHATIC SYSTEM DISEASE;
MAJOR CLINICAL STUDY;
MEDICAL ASSESSMENT;
METABOLIC AND NUTRITIONAL SKIN DISEASE;
MUSCULOSKELETAL DISEASE;
NEUROLOGIC DISEASE;
OUTPATIENT CARE;
PHYSICAL DISEASE;
RANDOMIZED CONTROLLED TRIAL;
RESPIRATORY TRACT DISEASE;
SCORING SYSTEM;
SKIN DISEASE;
SQUAMOUS CELL CARCINOMA;
STATISTICAL ANALYSIS;
UROGENITAL TRACT DISEASE;
ADMINISTRATION, TOPICAL;
ADOLESCENT;
ADULT;
ANALYSIS OF VARIANCE;
DICLOFENAC;
DOUBLE-BLIND METHOD;
DRUG ADMINISTRATION SCHEDULE;
DRUG COMBINATIONS;
FEMALE;
FOLLOW-UP STUDIES;
GELS;
HUMANS;
HYALURONIC ACID;
MALE;
MIDDLE AGED;
POROKERATOSIS;
PROBABILITY;
REFERENCE VALUES;
TREATMENT OUTCOME;
|
|
EID: 0035659622
PISSN: 00119059
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1365-4362.2001.01324.x Document Type: Article |
|
Times cited : (219)
|
|
References (20)
|
